In a 24-week randomized placebo-controlled trial, volunteers with elevated
uric acid levels who received twice-daily capsules of 500 mg T. bellerica
extract demonstrated a notable 9.8% average decrease in uric acid levels after
only 4 weeks. At the end of the study, uric acid levels were reduced by a
remarkable 28.4%, with no reported adverse side effects. This decrease in uric
acid levels enabled 89% of the participants who were taking the extract to
achieve targeted uric acid serum levels. Further, evidence from pre-clinical
studies suggest that the bioactive compounds in T. bellerica may also help
support a healthy response to inflammatory factors and has antioxidant
properties.
Features:
- The bioactive compounds in Terminalia bellerica are also believed to provide a healthy inflammatory response, possibly due to inhibition of inducible nitric oxide synthase (iNOS).
- In a 24-week active-control trial, volunteers with elevated uric acid levels who received twice-daily capsules of 500 mg of T. bellerica extract demonstrated decreased uric acid levels by a mean of 27.59%, with no reported adverse side effects.
- This decrease in uric acid levels enabled 88.8% of the people in the study arm who were taking the extract to achieve targeted uric acid serum levels.